Clal Biotechnology reported ILS16.49M in Cost of Sales for its fiscal quarter ending in June of 2022.





Cost Of Sales Change Date
aTyr Pharma USD 3.34M 18.79M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 3.54M 1.89M Dec/2025
Infinity Pharmaceuticals USD 352K 89K Jun/2023
Minerva Neurosciences 386K 31K Jun/2024
RedHill Biopharma USD 702K 0 Jun/2024
TherapeuticsMD USD -11.99M 12.34M Dec/2022